| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,
*
Department of Internal Medicine, University of Iowa, Iowa City, IA 52242;
Veteran Affairs Medical Center, Iowa City, IA 52246;
CpG ImmunoPharmaceuticals GmbH, Hilden, Germany; and
CpG ImmunoPharmaceuticals, Inc., Wellesly, MA 02481
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
B
p50/p65 heterodimer and of the transcription-factor complex AP-1.
Transcription-factor activation by CpG DNA was preceded by increased
phosphorylation of the stress kinases c-Jun N-terminal kinase and p38,
and of activating transcription factor-2. In contrast to CpG, signaling
through the B cell receptor led to activation of extracellular receptor
kinase and to phosphorylation of a different isoform of c-Jun
N-terminal kinase. These studies define the structure of a highly
active human CpG motif and characterize its molecular mechanism of
action in primary human B cells. |
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
CpG DNA is known to be an excellent immune adjuvant in various murine
disease models and to drive Th1 immune responses (16, 17, 18, 19, 20, 21).
Thus, CpG DNA might be useful for immunotherapy of allergy, infectious
disease, and cancer (20, 22, 23, 24). The potent adjuvant
activity of CpG DNA in mice is most likely based on its stimulatory
effects on dendritic cells and B cells. Although CpG effects in mice
are well characterized, information regarding the human system is
limited. Many CpG phosphorothioate oligodeoxynucleotides
(ODNs)3 with strong
stimulatory activity in the mouse system show only low activity on
human immune cells (A. M. Krieg, unpublished observations). In
human PBMCs, synthetic phosphodiester ODNs with hexamer palindromic
sequences containing a central CpG dinucleotide have been described as
inducing IFN-
synthesis (25). To date, the most active
phosphorothioate oligonucleotide reported to stimulate human B cells is
a 27-mer ODN (DSP30) originally designed as an antisense ODN to the
rev gene of HIV (26, 27, 28). A 21 mer
(27) and a 15 mer (29), both 3'-truncated
forms of the original anti-rev 27 mer, were equally
active as the complete 27 mer. DSP30 contains the sequence 5'-TCGTCG-3'
at its 5' end, suggesting the hypothesis that repeating TCG
motifs may activate human B cells. However, phosphorothioate ODNs
containing (TCG)n showed a lower activity than
DSP30 did (29). Furthermore, testing of phosphorothioate
ODNs which were not related to DSP30 but contained multiple copies of
various mouse 6-mer CpG motifs (GACGTT; TGACGTT; GACGTC; and TGACGTC)
were also less active than DSP30 (29). A
non-CpG-specific effect mediated by the phosphorothioate backbone was
suggested to be mainly responsible for the proliferative response in
these studies. Non-CpG-specific activation of human PBMCs by the
phosphorothioate backbone has been described earlier (30).
Thus, although human cells can be stimulated by a variety of ODNs, the
requirement for CpG dinucleotides and the optimal flanking bases, if
any, remain unclear.
The identification of a potent human CpG motif is critical for the transfer of therapeutic strategies derived from animal models to clinical settings. We recently demonstrated that CpG DNA induces activation of human monocytes (31) and dendritic cells (32), effects which are distinct from LPS-mediated effects. The goal of the present study is to systematically search for an optimal human CpG motif, to determine its functional effects on human B cells, and to elucidate its molecular mechanism of action.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Unmodified (phosphodiester) and modified nuclease-resistant
(phosphorothioate) ODNs were purchased from Operon Technologies
(Alameda, CA) and Hybridon Specialty Products (Milford, MA). The
sequences used are provided in Table I
.
Escherichia coli DNA and calf thymus DNA were
purchased from Sigma (St. Louis, MO). Genomic DNA samples were purified
by extraction with phenol-chloroform-isoamyl alcohol (25/24/1) and
ethanol precipitation. DNA was purified from endotoxin by repeated
extraction with Triton X-114 (Sigma) and tested for endotoxin using the
LAL assay (BioWhittaker, Walkersville, MD; lower detection limit 0.1
EU/ml) and the high-sensitivity assay for endotoxin described earlier
(lower detection limit 0.0014 EU/ml) (31). Endotoxin
content of DNA samples was below 0.0014 U/ml. E. coli and
calf thymus DNA were made single stranded before use by boiling for 10
min and then cooling on ice for 5 min. DNA samples were diluted in TE
buffer using pyrogen-free reagents.
|
Human PBMCs were isolated from peripheral blood of healthy
volunteers by Ficoll-Paque density gradient centrifugation
(Histopaque-1077, Sigma) as described (33). Cells were
suspended in RPMI 1640 culture medium supplemented with 10% (v/v)
heat-inactivated (56°C, 1 h) FCS (HyClone, Logan, UT), 1.5 mM
L-glutamine, 100 U/ml penicillin, and 100 µg/ml
streptomycin (all from Life Technologies, Grand Island, NY) (complete
medium). All compounds were purchased endotoxin tested. Viability was
determined before and after incubation with ODN by trypan blue
exclusion (conventional microscopy) or by propidium iodide exclusion
(flow cytometric analysis). In all experiments, 96–99% of PBMCs were
viable. Cells (final concentration, 1 x 106
cells/ml) were cultured in complete medium in a 5%
CO2-humidified incubator at 37°C. Different
ODNs (see Table I
; concentration as indicated in the figure legends),
LPS (from Salmonella typhimurium; Sigma), or anti-IgM
were used as stimuli. Chloroquine (5 µg/ml; Sigma) was used to block
endosomal maturation/acidification. At the indicated time points, cells
were harvested for flow cytometry as described below.
For signal transduction studies, human primary B cells were isolated by immunomagnetic cell sorting using the VARIOMACS technique (Miltenyi Biotec, Auburn, CA) as described by the manufacturer. In brief, PBMCs obtained from buffy coats of healthy blood donors (Elmer L. DeGowin Blood Center, University of Iowa) were incubated with a microbeads-conjugated Ab to CD19 and passed over a positive selection column. Purity of B cells was higher than 95%. After stimulation, whole cellular extracts (Western blot) and nuclear extracts (EMSA) for signal-transduction studies were prepared at the indicated time points.
Flow cytometry
Staining of surface Ags was performed as previously described
(34). mAbs to HLA-DR were purchased from Immunotech
(Marseille, France). All other Abs (mAbs to CD19 (B43), CD40 (5C3),
CD54 (HA58), and CD86 (2331 (FUN-1)) were purchased from PharMingen
(San Diego, CA). IgG1, (MOPC-21) and IgG2b, (27, 28, 29, 30, 31, 32, 35, 36, 37) were used to control for specific staining.
Intracellular cytokine staining for IL-6 was performed as described
(31). In brief, PBMCs (final concentration, 1 x
106 cells/ml) were incubated in the presence of
brefeldin A (final concentration, 1 µg/ml; Sigma). After incubation,
cells were harvested and stained using a FITC-labeled mAb to CD19
(B43), a PE-labeled rat anti-human IL-6 mAb (MQ2-6A3, PharMingen),
and the Fix and Perm Kit (Caltag Laboratories, Burlingame, CA). Flow
cytometric data of 5000 cells/sample were acquired on a FACScan (Becton
Dickinson Immunocytometry Systems, San Jose, CA). Nonviable cells were
excluded from analysis by propidium iodide staining (2 µg/ml). Data
were analyzed using the computer program FlowJo (version 2.5.1, Tree
Star, Stanford, CA).
Proliferation assay
CFSE (5-(and-6-) carboxyfluorescein diacetate succinimidyl ester; Molecular Probes, Eugene, OR) is a fluorescein-derived intracellular fluorescent label which is divided equally among daughter cells upon cell division. Staining of cells with CFSE allows both quantification and immunophenotyping (PE-labeled Abs) of proliferating cells in a mixed-cell suspension. Briefly, PBMCs were washed twice in PBS, resuspended in PBS containing CFSE at a final concentration of 5 µM, and incubated at 37°C for 10 min. Cells were washed three times with PBS and incubated for 5 days as indicated in the figure legends. Proliferating CD19-positive B cells were identified by decreased CFSE content using flow cytometry.
Preparation of whole-cell, nuclear, and cytosolic protein extracts
For Western blot analysis, whole-cell extracts were prepared. Primary B cells were treated with medium, the phosphodiester ODNs 2080 (CpG) or 2078 (non-CpG) at 30 µg/ml, or anti-IgM (10 µg/ml) as indicated. Cells were harvested, washed twice with ice-cold PBS containing 1 mM Na3VO4, resuspended in lysis buffer (150 mM NaCl, 10 mM Tris (pH 7.4), 1% Nonidet P-40 (NP-40), 1 mM Na3VO4, 50 mM NaF, 30 mg/ml leupeptin, 50 mg/ml aprotinin, 5 mg/ml antipain, 5 mg/ml pepstatin, and 50 µg/ml PMSF), incubated for 15 min on ice, and spun at 14,000 rpm for 10 min. The supernatant was frozen at -80°C. For the preparation of nuclear extracts, primary B cells were resuspended in hypotonic buffer (10 mM HEPES/KOH (pH 7.9), 10 mM KCl, 0.05% NP-40, 1.5 mM MgCl2, 0.5 mM DTT, 0.5 mM PMSF, 30 mg/ml leupeptin, 50 mg/ml aprotinin, 5 mg/ml antipain, and 5 mg/ml pepstatin). After 15 min incubation on ice, the suspension was centrifuged at 1000 x g for 5 min. The pelleted nuclei were resuspended in extraction buffer (20 mM HEPES (pH 7.9), 450 mM NaCl, 50 mM NaF, 20% glycerol, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF, 30 mg/ml leupeptin, 50 mg/ml aprotinin, 5 mg/ml antipain, and 5 mg/ml pepstatin) and incubated on ice for 1 h. The nuclear suspension was centrifuged for 10 min at 16,000 x g at 4°C. Supernatant was collected and stored at -80°C. Cytosolic extracts for the CpG-binding protein studies were prepared from unstimulated Ramos cells, which were lysed with hypotonic buffer as described for the preparation of the nuclear extract. After centrifugation, the supernatant was removed as cytoplasmic fraction and stored at -80°C. Protein concentrations were measured using a Bradford protein assay (Bio-Rad, Hercules, CA) according to the manufacturer’s instructions.
Western blot analysis
Equal concentrations of whole-cell protein extracts (25 µg/lane) were boiled in SDS sample buffer (50 mM Tris-Cl (pH 6.8), 1% 2-ME, 2% SDS, 0.1% bromphenol blue, and 10% glycerol) for 4 min before being subjected to electrophoresis on a 10% polyacrylamide gel containing 0.1% SDS (SDS-PAGE). After electrophoresis, proteins were transferred to Immobilon-P transfer membranes (Millipore, Bedford, MA). Blots were blocked with 5% nonfat dry milk. Specific Abs against the phosphorylated form of extracellular receptor kinase (ERK), c-Jun N-terminal kinase (JNK), p38, and activating transcription factor-2 (ATF-2) were used (New England Biolabs, Beverly, MA). Blots were developed in enhanced chemiluminescence reagent (Amersham International, Aylesbury, U.K.) according to the manufacturer’s recommended procedure.
EMSA
To detect the DNA-binding activity of the transcription factor
AP-1 and NF-B, nuclear extracts (1 µg/lane) were analyzed by EMSA
using the dsODNs 5'-GAT CTA GTG ATG AGT CAG CCG GAT C-3' containing the
AP-1 binding sequence and the NF-B upstream regulatory element (URE)
from the c-myc promotor region 5'-TGC AGG AAG TCC GGG TTT
TCC CCA ACC CCC C-3' as probes. ODNs were end labeled with
T4-polynucleotide kinase (New England Biolabs) and
[
-32P]ATP (Amersham, Arlington Heights, IL).
Binding reactions were performed with 1 µg nuclear protein extract in
DNA-binding buffer (10 mM Tris-HCl (pH 7.5), 40 mM
MgCl2, 20 mM EDTA, 1 mM DTT, 8% glycerol, and
100–400 ng of poly(dI-dC) with 20,000–40,000-cpm-labeled ODN in 10
µl total volume). Specificity of the NF-B bands was confirmed by
competition studies with cold ODNs from unrelated transcription-factor
binding sites (10–100 ng). For the supershift assay, 2 µg of
specific Abs for c-rel, p50, and p65 (Santa Cruz
Biotechnology, Santa Cruz, CA) were added into the reaction mixture for
30 min before the radiolabeled probe was added. After incubation for 30
min at room temperature, loading buffer was added and the probes were
electrophoresed on a 6% polyacrylamide gel in Tris-borate-EDTA running
buffer (90 mM Tris, 90 mM boric acid, 2 mM EDTA (pH 8.0)). Gels were
dried and then autoradiographed.
Statistical analysis
Data were expressed as means ± SEM. Statistical significance of differences was determined by the unpaired two-tailed Student t test. Differences were considered statistically significant for p < 0.05. Statistical analyses were performed by using StatView 4.51 software (Abacus Concepts, Calabasas, CA).
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Phosphorothioate ODNs containing the murine CpG motif
GACGTT (for example ODN 1826) and used at concentrations
which are highly active on murine B cells (3) show little
or no immunostimulatory activity on human immune cells (data not
shown). Added at high concentrations, phosphorothioate ODNs stimulate
human B cells in a CpG-independent manner (29). This
likely is due to the phosphorothioate modification of the ODNs. The use
of bacterial DNA or unmodified phosphodiester ODNs avoids the
sequence-independent background activity of the phosphorothioate
backbone. We found that B cells express increased levels of the
costimulatory molecule CD86 (B7-2) in response to CpG DNA but not in
response to non-CpG control DNA (Fig. 1).
Assuming that bacterial DNA contains human CpG motifs, we tested the
effect of highly purified E. coli DNA (31) on
human primary B cells. Repeated addition (at 0, 4, and 8 h) of 30
µg/ml E. coli DNA resulted in maximal expression of CD86
on human B cells within 2 days. Higher concentrations showed no further
increase. Calf thymus DNA (non-CpG control DNA) did not activate human
B cells. High concentrations of LPS (1 µg/ml, 1000-fold more than
needed for maximal activation of human monocytes) only slightly
activated B cells above background (mean fluorescence intensity (MFI)
CD86: E. coli DNA, 3.4 ± 0.9; calf thymus DNA,
1.5 ± 0.4; LPS 1.6 ± 0.4; medium only, 0.9 ± 0.1;
n = 4).
|
Using this information we designed a 20-mer phosphodiester ODN with a
TpC dinucleotide at the 5' end preceding the optimal murine CpG motif
5'-GACGTT-3' and followed by a poly C tail (2079,
5'-TCG ACG TTC CCC CCC CCC CC-3'). This ODN, if
added to human primary B cells under the same conditions found to be
optimal for E. coli DNA (repeated addition at 0, 4, and
18 h; 30 µg/ml for each time point), stimulated high levels of
CD86 expression on human primary B cells after 2 days (Fig. 2). To determine the structure-function
relationship of the CpG motifs, we replaced the bases adjacent to the
CpG dinucleotides while maintaining the two CpG dinucleotides within
the sequence. Exchange of the adenine located between both CpG
dinucleotides by thymidine (2080) resulted in slightly higher activity
(Fig. 2). Replacement by guanosine (2100) or cytidine (2082) at this
position showed no major changes compared with 2079. In contrast,
replacement of the thymidine 3' to the second CpG dinucleotide by the
purines guanosine (2099) or adenine (2083) resulted in a major drop in
activity of the ODN, whereas the pyrimidine cytidine caused only a
minor decrease (Fig. 2). The thymidine immediately 5' to the first CpG
dinucleotide was also critical. Replacement of the thymidine by any
other base (e.g., 2105, guanosine; 2107, adenine; or 2104, cytidine)
led to a marked decrease in activity of the ODN. Elimination of the
first (2108) or the second (2106) CpG dinucleotide also partially
reduced the activity (Fig. 2).
|
). Methylation of an
unrelated cytidine (2094) did not change the potency to activate B
cells. An ODN with an inversion of both CpG dinucleotides to GpC (2078)
and another non-CpG control ODN derived from 2080 (2101; Table I and
data not shown) did not stimulate CD86 expression above background
(Fig. 2).
The addition of more 5'-GTCGTT-3' CpG motifs to the
phosphodiester ODN containing the 8-mer duplex CpG motif
(5'-TCGTCGTT-3', 2080) did not further enhance
CD86 expression on B cells (2059). An ODN with the same sequence as
2080 but with a phosphorothioate backbone showed no activity above
background (2116). This was surprising because the phosphorothioate
backbone has been reported to greatly stabilize ODNs and to enhance
CpG-induced stimulation (2). Therefore, we performed
further structure-function analyses of phosphorothioate ODNs containing
the 5'-GTCGTT-3' and 5'-TCGTCGTT-3'
motifs, which showed that an active phosphorothioate ODN required the
presence of additional CpG motifs (2006) (Fig. 2, and Hartmann et al.,
manuscript in preparation). Although the maximal activities of
phosphodiester and phosphorothioate ODNs were similar, much lower
concentrations of the phosphorothioate ODN (0.6 µg/ml) were
sufficient to produce maximal activity, most likely due to the higher
nuclease stability of the phosphorothioate backbone. The effect of 2006
at this concentration was CpG-specific because a control ODN with the
same sequence but with methylated cytidines (2117) did not induce CD86
expression on primary B cells (MFI CD86: 2006, 8.4 ± 1.2; 2117,
2.4 ± 0.3; medium only, 2.3 ± 0.2; n =
3).
Purified B cells isolated from peripheral blood by immunomagnetic cell sorting were activated by CpG DNA to the same extent as unpurified B cells within PBMCs (data not shown). Thus, activation of B cells is a primary response and not a secondary effect caused by cytokines secreted by other cells.
Induction of CD40, CD54, and MHC class II (MHC-II) expression and IL-6 synthesis by CpG DNA
In addition to the costimulatory molecule CD86, the functional
state of B cells is characterized by other surface markers. For
example, activated T helper cells stimulate B cells by CD40 ligation,
ICAM-1 (CD54) mediates binding to other immune cells, and MHC-II is
responsible for Ag presentation. We found that B cell expression of
CD40, CD54, and MHC-II was up-regulated by the CpG ODN 2080 (Fig. 3). The non-CpG control ODN 2078 (CpG
inverted to GpC) showed no activity compared with medium alone.
|
Sequence-dependent induction of B cell proliferation by CpG DNA
When PBMCs were incubated for 5 days in the presence of 2080
(added at 0, 4, and 18 h and every subsequent morning), it was
intriguing that a subpopulation of lymphocytes increased in cell size
(forward light scatter (FSC)) and became more granular (side light
scatter) (Fig. 4, upper
panel). To examine whether this subpopulation represented
proliferating B cells, we stained freshly isolated PBMCs with CFSE at
day 0 and incubated them for 5 days with 2080 as above. CFSE is a
fluorescent molecule that binds irreversibly to cell proteins. Each
cell division decreases CFSE stain by 50% (35). Cells
staining low with CFSE (proliferating cells) were found to be mainly
CD19-positive B cells (Fig. 4, middle panel). The ODN 2080
induced 60–70% of CD19-positive B cells to proliferate within 5 days.
The control ODN 2078 induced less than 5% of B cells to proliferate.
Proliferating B cells (CFSE-low) showed a larger cell size (FSC) and
higher granularity (Fig. 4, lower panel).
|
). Replacement of the 3' thymidine
reduced activity more than changing the thymidine in the middle
position. Methylation of the CpG dinucleotides (2095) blocked activity,
whereas methylation of an unrelated cytidine (2094) did not influence
the capacity to induce B cell proliferation. Activity of E.
coli DNA was lower than activity of 2080. LPS did not induce B
cell proliferation.
|
It has been shown earlier that chloroquine, an inhibitor of endosomal acidification, blocks CpG-mediated stimulation of murine APCs and B cells, but does not influence LPS-mediated effects (8, 15, 36). We found that the addition of 5 µg/ml chloroquine completely blocked CpG DNA-mediated induction of CD86 expression on primary B cells (MFI CD86: 2006, 4.7 vs 1.4; E. coli DNA, 3.4 vs 1.4; medium only, 0.9; n = 4). Furthermore, chloroquine completely inhibited the induction of B cell proliferation by the phosphorothioate ODN 2006 measured with the CFSE proliferation assay as well as with the standard. These results suggest that, as with murine cells, activation of human B cells by CpG DNA requires the uptake of DNA in endosomes and subsequent endosomal acidification.
CpG DNA stimulates rapid and sustained NF-B binding activity in
human B cells
Because the CpG motif requirement for maximal B cell activation is
substantially different between mice (GACGTT) and humans
(TCGTCGTT), we were interested in whether the
basic intracellular signaling events are comparable. This information
will help to extrapolate from mouse studies to responses of the human
immune system. Rapid induction of NF-B binding activity has been
found earlier in murine B cells and macrophages (6, 15).
To investigate the NF-B response to CpG DNA in humans, human primary
B cells were isolated from peripheral blood by immunomagnetic cell
sorting and incubated with the CpG ODN 2080, the non-CpG control ODN
2078, or medium. At the indicated time points, cells were harvested and
nuclear extracts were prepared. In the presence of CpG ODN, NF-B
binding activity was increased within 1 h and maintained up to
18 h (latest time point examined) (Fig. 6). The non-CpG control ODN 2078 did not
show enhanced NF-B activity compared with cells incubated with
medium only. The NF-B band was identified by cold competition and
shown to consist of p50 and p65 subunits by supershift assay (Fig. 6).
|
The AP-1 transcription factor is involved in the regulation of
immediate early genes and cytokine expression (37). In
murine B cells, AP-1-binding activity is induced in response to CpG DNA
(13). To determine whether this transcription factor would
also be induced by CpG DNA in humans, we examined AP-1 DNA-binding
activity in human primary B cells. Cells were incubated with the CpG
ODN 2080 or the control ODN 2078. At the indicated time points, nuclear
extracts were prepared and the AP-1-binding activity was analyzed by
EMSA. AP-1-binding activity was enhanced within 1 h (Fig. 7A) and increased up to
18 h (latest time point examined), showing a sustained
response.
|
Because AP-1 activity is induced by many stimuli
(38), we were interested in signal-transduction pathways
upstream of AP-1. The AP-1 transcription-factor complex integrates
different mitogen-activated protein kinase pathways (37).
Western blots were performed using whole-cell extracts from primary B
cells incubated with the CpG ODN 2080, the control 2078, or medium
only. Specific Abs to the phosphorylated form of JNK, p38, ATF-2, and
ERK were used. Strong induction of JNK phosphorylation was found 30 and
60 min after exposure to CpG DNA, whereas the non-CpG ODN showed no
activity above background (Fig. 7B). The protein kinase p38,
another stress-activated protein kinase (SAPK), was also phosphorylated
in response to CpG DNA within 60 min. ATF-2, a substrate of both p38
and JNK (39) and a component of the AP-1 complex, showed
weak phosphorylation after 30 min which increased after 60 min. CpG DNA
failed to induce substantial phosphorylation of ERK. In contrast,
anti-IgM, stimulating the B cell receptor, did trigger
phosphorylation of ERK. Anti-IgM activated different isoforms of JNK
than CpG DNA did (Fig. 7B).
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
B and AP-1, as
well as phosphorylation of the stress-activated protein kinases JNK and
p38 and the transcription factor ATF-2. B cell signaling pathways
activated by CpG DNA were different from those activated by the B cell
receptor, which activated ERK and a different isoform of JNK, but did
not activate p38 and ATF-2. Blockade of endosomal maturation with
chloroquine abolished these effects. The use of phosphodiester ODNs facilitates the identification of an active CpG motif. Base exchanges within the most potent 8-mer CpG motif (5'-TCGTCGTT-3') diminished the activity of the ODN. The thymidines at the 5' and the 3' positions of this motif were more critical than the thymidine at the middle position. An adenine or guanosine at the middle position only slightly decreased the activity but resulted in a CpG dinucleotide flanked by two 5' purines and two 3' pyrimidines, a 6-mer sequence which was previously identified to be the optimal murine CpG motif (2). The significant change compared with the mouse motif is the additional requirement of a 5' TC adding a second CpG. Although the human CpG motif is still active in mice (data not shown), the murine 6-mer CpG motif alone is not sufficient to produce high activity in humans. This argues for a refinement of the CpG recognition mechanism in primates.
CpG effects on B cells were strictly CpG specific. Replacement of CpG dinucleotides with GpC dinucleotides as well as cytidine methylation of the CpG dinucleotides abolished B cell activation. The methylation of an unrelated cytidine did not change the activity of the CpG ODN. Due to degradation by nucleases, detection of immune stimulation by phosphodiester ODNs required that they be added several times at relatively high concentration (30 µg/ml). Even at these high concentrations, phosphodiester ODNs without CpG dinucleotides showed no background activity.
The development of CpG DNA as a practical drug requires nuclease resistance such as is conferred by the phosphorothioate backbone which protects DNA from rapid degradation in vivo (2). Of note, our studies demonstrate that one human CpG motif within a phosphodiester ODN (2080) is sufficient to produce the maximal effect and that additional CpG motifs (2059) did not further enhance the activity. Surprisingly, the phosphorothioate modification completely abolished the immunostimulatory activity of an ODN with only one human CpG motif (2116), and additional CpG motifs were required to regain activity (2006). Furthermore, phosphorothioate ODNs with the murine CpG motif highly stimulatory to murine immune cells showed only low activity in human B cells (our unpublished results). Thus, the use of the phosphorothioate backbone requires the optimal CpG motif, whereas phosphodiester ODNs still show some activity if the motif is slightly changed. This suggests that the specificity or affinity of the interaction between the CpG DNA and a putative CpG binding protein is reduced by the phosphorothioate backbone. This is supported by EMSA studies in which we have been unable to detect binding of phosphorothioate CpG ODNs to a putative CpG-binding protein (data not shown) under conditions where phosphodiester CpG DNA binds well.
The nuclease-resistant phosphorothioate backbone dramatically reduced the concentration of an ODN required for maximal activity (0.6 µg/ml). At this concentration, B cell stimulation was CpG-specific and little background stimulation by the phosphorothioate backbone was found. Others have reported that, in contrast to phosphorothioate ODNs, both bacterial DNA and CpG phosphodiester ODNs (phosphodiester forms of active CpG phosphorothioate ODNs) failed to induce proliferation of human B cells even when added repeatedly and in concentrations up to 100 µg/ml (29). However, in that study proliferation was only measured by [3H]thymidine, which can give misleading results because degradation products of unmodified DNA inhibit incorporation of [3H]thymidine by proliferating cells (40). In the present study we used the CFSE proliferation assay which is not sensitive to this potential artifact and clearly demonstrated sequence-specific effects of both phosphodiester and phosphorothioate DNA on human B cells.
The molecular mechanism by which CpG DNA activates human B cells has
been unclear. Murine B cells do not appear to have a CpG-specific
membrane receptor because no difference in their binding of
fluorescence-labeled CpG and non-CpG ODNs could be detected, and CpG
ODNs linked to a solid support are nonstimulatory (2). In
the present study chloroquine abolished CpG-mediated B cell activation,
confirming that uptake of ODNs into the endosomal compartment and
subsequent endosomal maturation is required in the human system. It has
been hyothesized that a yet undefined CpG-binding protein downstream of
endosomal maturation specifically recognizes and binds CpG motifs
(13, 36). We hypothesize that upon binding to the putative
binding protein, CpG DNA induces a rapid and sustained increase in
NF-B-binding activity in human primary B cells. NF-B p50/p65 was
found to be the major nuclear heterodimer in human primary B cells in
response to CpG DNA. This is in agreement with earlier findings showing
that inducible NF-B in mature B cells consists mainly of the p50/Rel
heterodimer, whereas p50 and p65 are the major components in immature B
cells (41).
CpG DNA stimulated a rapid and sustained increase of AP-1-binding activity in primary human B cells. AP-1, a transcription-factor complex comprised of members of the Fos, Jun, and ATF families, is involved in the regulation of immediate early genes and the expression of cytokines. AP-1 integrates signals from several signal-transduction pathways (37). Different types of mitogen-activated protein kinases contribute to the activity of AP-1. Among those are the SAPKs and the ERKs. In the present study, the SAPKs JNK (42) and p38, another SAPK originally identified as a kinase activated by LPS (43), were rapidly phosphorylated in human primary B cells in response to CpG DNA. Analogous to murine B cells, CpG DNA induced different isoforms of JNK in human B cells (13). ATF-2 (44), a substrate of both p38 and JNK (39), was also phosphorylated in response to CpG DNA. Interestingly, the ERK was activated by ligation of the B cell receptor on human B cells but not in response to CpG DNA. Taken together, our data on CpG DNA-initiated signal transduction are consistent with those obtained in mice (8, 13).
In conclusion, the discovery and the characterization of a highly active human CpG motif allows an extrapolation from mouse disease models to human therapeutic settings using CpG DNA. The nuclease-resistant human CpG phosphorothioate ODN 2006 and related ODNs are candidates to be tested in clinical trials as adjuvants for vaccination strategies including those for cancer, allergy, and infectious diseases. The delineation of an optimal human CpG motif forms the basis for further studies on the identification of the putative CpG-binding protein and on how the recognition of CpG DNA by this protein is translated into downstream signaling pathways.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Arthur Krieg, Department of Internal Medicine, University of Iowa, 540 EMRB, Iowa City, IA 52242. E-mail address:
3 Abbreviations used in this paper: ODN, oligodeoxynucleotides; ERK, extracellular receptor kinase; JNK, c-Jun N-terminal kinase; ATF-2, activating transcription factor-2; MFI, mean fluorescence intensity; MHC-II, MHC class II; FSC, forward light scatter; CFSE, (5-(and-6-) carboxyfluorescein diacetate succinimidyl ester; SAPK, stress-activated protein kinase.
Received for publication July 27, 1999. Accepted for publication October 28, 1999.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
production is dependent on macrophage secretion of IL-12. Clin. Immunol. Immunopathol. 84:185.[Medline]
in vivo and increases the toxicity of lipopolysaccharides. J. Immunol. 156:4570.[Abstract]
synthesis by antisense oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev. 6:291.[Medline]
B/Rel family proteins during B-cell terminal differentiation. Mol. Cell. Biol. 14:5349.This article has been cited by other articles:
|
|
 |
|
  C. T. Ranjith-Kumar, K. E. Duffy, J. L. Jordan, A. Eaton-Bassiri, R. Vaughan, S. A. Hoose, R. J. Lamb, R. T. Sarisky, and C. C. Kao Single-Stranded Oligonucleotides Can Inhibit Cytokine Production Induced by Human Toll-Like Receptor 3 Mol. Cell. Biol., July 15, 2008; 28(14): 4507 - 4519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hoelzer, L. A. Shackelton, and C. R. Parrish Presence and role of cytosine methylation in DNA viruses of animals Nucleic Acids Res., May 1, 2008; 36(9): 2825 - 2837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Mizgerd and S. J. Skerrett Animal models of human pneumonia Am J Physiol Lung Cell Mol Physiol, March 1, 2008; 294(3): L387 - L398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Mapletoft, M. Oumouna, J. Kovacs-Nolan, L. Latimer, G. Mutwiri, L. A. Babiuk, and S. van Drunen Littel-van den Hurk Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection J. Gen. Virol., January 1, 2008; 89(1): 250 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. A. Ivory, M. Prystajecky, C. Jobin, and K. Chadee Toll-Like Receptor 9-Dependent Macrophage Activation by Entamoeba histolytica DNA Infect. Immun., January 1, 2008; 76(1): 289 - 297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kindrachuk, J. E. Potter, R. Brownlie, A. D. Ficzycz, P. J. Griebel, N. Mookherjee, G. K. Mutwiri, L. A. Babiuk, and S. Napper Nucleic Acids Exert a Sequence-independent Cooperative Effect on Sequence-dependent Activation of Toll-like Receptor 9 J. Biol. Chem., May 11, 2007; 282(19): 13944 - 13953. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ertesvag, H.-C. Aasheim, S. Naderi, and H. K. Blomhoff Vitamin A potentiates CpG-mediated memory B-cell proliferation and differentiation: involvement of early activation of p38MAPK Blood, May 1, 2007; 109(9): 3865 - 3872. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Bekeredjian-Ding, S. Inamura, T. Giese, H. Moll, S. Endres, A. Sing, U. Zahringer, and G. Hartmann Staphylococcus aureus Protein A Triggers T Cell-Independent B Cell Proliferation by Sensitizing B Cells for TLR2 Ligands J. Immunol., March 1, 2007; 178(5): 2803 - 2812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Andersen-Nissen, K. D. Smith, R. Bonneau, R. K. Strong, and A. Aderem A conserved surface on Toll-like receptor 5 recognizes bacterial flagellin J. Exp. Med., February 19, 2007; 204(2): 393 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Hoene, M. Peiser, and R. Wanner Human monocyte-derived dendritic cells express TLR9 and react directly to the CpG-A oligonucleotide D19 J. Leukoc. Biol., December 1, 2006; 80(6): 1328 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Leifer, J. C. Brooks, K. Hoelzer, J. Lopez, M. N. Kennedy, A. Mazzoni, and D. M. Segal Cytoplasmic Targeting Motifs Control Localization of Toll-like Receptor 9 J. Biol. Chem., November 17, 2006; 281(46): 35585 - 35592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Hartmann, H. Graefe, A. Hopert, R. Pries, S. Rothenfusser, H. Poeck, B. Mack, S. Endres, G. Hartmann, and B. Wollenberg Analysis of Plasmacytoid and Myeloid Dendritic Cells in Nasal Epithelium Clin. Vaccine Immunol., November 1, 2006; 13(11): 1278 - 1286. [Abstract] [Full Text] [PDF]
|
|
